GnT-IVA Inhibitors
Chemical inhibitors of GnT-IVA function through various mechanisms to disrupt its role in the glycosylation pathway. Swainsonine targets alpha-mannosidase II, essential for mannose trimming in N-glycan synthesis, which is a prerequisite for the action of GnT-IVA. By blocking this enzyme, swainsonine indirectly hampers the function of GnT-IVA by preventing the proper formation of its glycoprotein substrates. Similarly, Kifunensine and Deoxymannojirimycin inhibit mannosidase I and II, respectively, which are enzymes that precede the action of GnT-IVA in the glycosylation cascade. The inhibition of these enzymes by Kifunensine and Deoxymannojirimycin leads to the accumulation of improperly processed glycans, which are not suitable substrates for GnT-IVA, thus functionally inhibiting it. Deoxynojirimycin and Castanospermine exert their effects earlier in the glycosylation process by inhibiting alpha-glucosidase I and II and glucosidase, respectively. This disruption in the early stages of glycan processing results in a shortage of mature substrates for GnT-IVA, which in turn limits its functional activity.
Bromoconduritol, Celgosivir, and Isofagomine are inhibitors of beta-glucosidases, alpha-glucosidases, and another form of beta-glucosidase, respectively. Their inhibition of these glycosidase enzymes affects the fine-tuning of glycan structures, which are essential for the functional activity of GnT-IVA. Without these structures being correctly formed, GnT-IVA cannot perform its role in modifying glycoproteins. Miglustat alters glycosphingolipid metabolism by inhibiting glucosylceramide synthase. This enzymatic block can change the membrane environment where GnT-IVA operates, indirectly leading to its functional inhibition. Salbostatin disrupts sugar phosphate pools through the inhibition of trehalose-6-phosphate phosphatase, which can impact the glycosylation reactions GnT-IVA catalyzes, thereby inhibiting its function. Genistein, being a tyrosine kinase inhibitor, can indirectly inhibit the activity of GnT-IVA by blocking N-linked glycosylation, a pathway in which GnT-IVA is directly involved.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $135.00 $246.00 $619.00 $799.00 $1796.00 | 6 | |
Swainsonine is an inhibitor of alpha-mannosidase II, an enzyme that is crucial for the trimming of mannose residues in N-glycans. By inhibiting this enzyme, the processing of N-glycans is disrupted, which is a necessary step for the proper function of GnT-IVA in glycoprotein synthesis. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $132.00 $529.00 $1005.00 $6125.00 | 25 | |
Kifunensine inhibits mannosidase I, which is upstream of the GnT-IVA in the glycosylation pathway. The inhibition of mannosidase I prevents the formation of substrates that GnT-IVA would typically act upon, thus functionally inhibiting GnT-IVA indirectly. | ||||||
Deoxymannojirimycin hydrochloride | 84444-90-6 | sc-201360 sc-201360A | 1 mg 5 mg | $93.00 $239.00 | 2 | |
Deoxymannojirimycin is an inhibitor of alpha-mannosidase I and II. By inhibiting these enzymes, the substrate maturation required for GnT-IVA activity is hindered, leading to a functional inhibition of the protein. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $72.00 $142.00 | ||
Deoxynojirimycin blocks alpha-glucosidase I and II, enzymes involved in the early stages of glycan processing. This inhibition affects the formation of GnT-IVA substrates, reducing its functional activity. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $180.00 $620.00 | 10 | |
Castanospermine is a glucosidase inhibitor that impairs the trimming of glucose residues in N-glycan assembly. This improper glycan assembly affects the action of enzymes like GnT-IVA that modify these glycans. | ||||||
Celgosivir | 121104-96-9 | sc-488385 sc-488385A sc-488385B | 5 mg 25 mg 100 mg | $525.00 $902.00 $2700.00 | ||
Celgosivir inhibits alpha-glucosidases, which are key enzymes in the proper folding and assembly of N-glycans. The inhibition of these glucosidases indirectly inhibits GnT-IVA by disrupting its glycan substrates. | ||||||
Isofagomine D-Tartrate | 957230-65-8 | sc-207767 sc-207767A sc-207767C sc-207767B | 5 mg 10 mg 50 mg 25 mg | $379.00 $710.00 $1975.00 $1199.00 | ||
Isofagomine acts as an inhibitor of beta-glucosidase, an enzyme involved in glycan modification. By inhibiting beta-glucosidase, the processing of N-glycans necessary for GnT-IVA function is disrupted. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor and has been shown to inhibit N-linked glycosylation. As GnT-IVA is involved in the N-glycosylation pathway, the inhibition of this pathway by Genistein leads to a functional inhibition of GnT-IVA. | ||||||